Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 6, 2003, Pages 945-949

  Ohara, Koichi ^a,b   Tanabu, Shigeru ^a   Yoshida, Kimiko ^a   Ishibashi, Kazuhisa ^a   Ikemoto, Keiko ^a   Shibuya, Haruo ^a  

^a National Hospital Organization Hanamaki Hospital   (Japan)

^b Kanagawa Pref Center for Psychiatry   (Japan)

Author keywords

Cytochrome P450; Haloperidol; Smoking

Indexed keywords

CYTOCHROME P450 2D6; HALOPERIDOL;

ADULT; AGED; ALLELE; ARTICLE; BODY WEIGHT; DEMENTIA; DNA POLYMORPHISM; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PLASMA CLEARANCE; SCHIZOPHRENIA; SMOKING;

EID: 0141740272     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00154-4     Document Type: Article

References (42)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Association, Washington, DC. DSM-IV.
2. Bertilsson L., Dahl M.L., Dalen P., Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53:2002;111-122.
3. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 3:2002;229-243.
4. Chida M., Yokoi T., Kosaka Y., Chiba K., Nakamura H., Ishizaki T., Yokota J., Kinoshita M., Sato K., Inaba M., Aoki Y., Gonzalez F.J., Kamataki T. Genetic polymorphism of CYP2D6 in the Japanese population. Pharmacogenetics. 9:1999;601-605.
5. Chong S.A., Choo H.L. Smoking among Chinese patients with schizophrenia. Aust. N. Z. J. Psychiatry. 30:1996;350-353.
6. Dainippon Pharmaceutical, 2001. Markit-M haloperidol affix paper.
7. de Leon J., Dadvand M., Canuso C., White A.O., Stanilla J.K., Simpson G.M. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am. J. Psychiatry. 152:1995;453-455.
8. Douglas A.M., Atchison B.A., Somogyi A.A., Drummer O.H. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics. 4:1994;154-158.
9. Froemming J.S., Lam Y.W., Jann M.W., Davis C.M. Pharmacokinetics of haloperidol. Clin. Pharmacokinet. 17:1989;396-423.
10. Goff D.C., Henderson D.C., Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am. J. Psychiatry. 149:1992;1189-1194.
11. Heim M., Meyer U.A. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 336:1990;529-532.
12. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry. 143:1986;993-997.
13. Ingelman-Sundberg M., Evans W.E. Unravelling the functional genomics of the human CYP2D6 gene locus. Pharmacogenetics. 11:2001;553-554.
14. Jann M.W., Saklad S.R., Ereshefsky L., Richards A.L., Harrington C.A., Davis C.M. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl.). 90:1986;468-470.
15. Johansson I., Oscarson M., Yue Q.Y., Bertilsson L., Sjöqvist F., Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46:1994;452-459.
16. Jokinen M.J., Olkkola K.T., Ahonen J., Neuvonen P.J. Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clin. Pharmacol. Ther. 70:2001;344-350.
17. Jusko W.J. Influence of cigarette smoking on drug metabolism in man. Drug Metab. Rev. 9:1979;221-236.
18. Kudo S., Ishizaki T. Pharmacokinetics of haloperidol. Clin. Pharmacokinet. 37:1999;435-456.
19. Kudo S., Odomi M. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur. J. Clin. Pharmacol. 54:1998;253-259.
20. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54:2002;1271-1294.
21. Leonard S., Breese C., Adams C., Benhammou K., Gault J., Stevens K., Lee M., Adler L., Olincy A., Ross R., Freedman R. Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur. J. Pharmacol. 393:2000;237-242.
22. Llerena A., Alm C., Ekqvist B., Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit. 14:1992;92-97.
23. Llerena A., Dahl M.L., Ekqvist B., Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype, increased plasma levels of the reduced metabolite in poor metabolizers. Ther. Drug Monit. 14:1992;261-264.
24. Mihara K., Suzuki A., Kondo T., Yasui N., Furukori H., Nagashima U., Otani K., Kaneko S., Inoue Y. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin. Pharmacol. Ther. 65:1999;291-294.
25. Miller D.D., Kelly M.W., Perry P.J., Coryell W.H. The influence of cigarette smoking on haloperidol pharmacokinetics. Biol. Psychiatry. 28:1990;529-531.
26. Miners J.O., Mackenzie P.I. Drug glucuronidation in humans. Pharmacol. Ther. 51:1991;347-369.
27. Nishida Y., Fukuda T., Yamamoto I., Azuma J. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics. 10:2000;567-570.
28. Pan L., Vander Stichele R., Rosseel M.T., Berlo J.A., De Schepper N., Belpaire F.M. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. Ther. Drug Monit. 21:1999;489-497.
29. Perry P.J., Miller D.D., Arndt S.V., Smith D.A., Holman T.L. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. J. Clin. Psychopharmacol. 13:1993;46-51.
30. Roh H.K., Chung J.Y., Oh D.Y., Park C.S., Svensson J.O., Dahl M.L., Bertilsson L. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br. J. Clin. Pharmacol. 52:2001;265-271.
31. Salokangas R.K., Saarijarvi S., Taiminen T., Lehto H., Niemi H., Ahola V., Syvalahti E. Effect of smoking on neuroleptics in schizophrenia. Schizophr. Res. 23:1997;55-60.
32. Shibata N., Ohnuma T., Baba H., Shimada H., Takahashi T., Arai H. Genetic association between cytochrome P-450 2D6 gene polymorphism and plasma concentration of haloperidol in Japanese schizophrenics. Psychiatr. Genet. 9:1999;145-148.
33. Shimoda K., Someya T., Morita S., Hirokane G., Noguchi T., Yokono A., Shibasaki M., Takahashi S. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. Ther. Drug Monit. 21:1999;293-296.
34. Shimoda K., Morita S., Yokono A., Someya T., Hirokane G., Sunahara N., Takahashi S. CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients. Ther. Drug Monit. 22:2000;392-396.
35. Someya T., Suzuki Y., Shimoda K., Hirokane G., Morita S., Yokono A., Inoue Y., Takahashi S. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. Psychiatry Clin. Neurosci. 53:1999;593-597.
36. Stassen H.H., Bridler R., Hagele S., Hergersberg M., Mehmann B., Schinzel A., Weisbrod M., Scharfetter C. Schizophrenia and smoking: evidence for a common neurobiological basis? Am. J. Med. Genet. 96:2000;173-177.
37. Suzuki A., Otani K., Mihara K., Yasui N., Kaneko S., Inoue Y., Hayashi K. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics. 7:1997;415-418.
38. Tsuneizumi T., Aoba A., Yamaguchi N. The effect of smoking on plasma neuroleptic levels of haloperidol and chlorpromazine. St. Marianna Med. J. 18:1990;298-305.
39. Weber W.W. Populations and genetic polymorphisms. Mol. Diagn. 4:1999;299-307.
40. Yasui N., Kondo T., Otani K., Furukori H., Mihara K., Suzuki A., Kaneko S., Inoue Y. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J. Clin. Psychopharmacol. 19:1999;149-154.
41. Yue Q.Y., Tomson T., Sawe J. Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics. 4:1994;193-198.
42. ZumBrunnen T.L., Jann M.W. Drug interactions with antipsychotic agents. CNS Drugs. 9:1998;381-401.